NewAmsterdam Pharma Company 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you for joining Guggenheim's third Healthcare Innovation Conference. My name is Moritz. I am part of the therapeutics team, and it is my privilege today to host Ian Somaiya, CFO of NewAmsterdam Pharma, and Matt Philippe, head of IR. Thank you so much for making time for us, Ian and Matt. To start with, perhaps let us get everybody on the same page.
Can you briefly summarize the status of your ongoing PREVAIL study and your plans for the upcoming interim analysis?
Yeah. No, happy to do that. Thanks again for inviting us and hosting us this morning. It was great to get in front of investors and share with everyone the NewAmsterdam story. October marked my three years at NewAmsterdam, and just in reflecting on my short time here, it is amazing to see the progress we have made as a company and how close we are to delivering on the promise of Obi and Obi/Eze. In those three years, we have had a company that has transitioned from delivering phase II data to now having completed the phase III LDL studies, with our partner launching, partner Menarini, launching the drug in Europe, specifically Germany, by the end of this year. It is a commercial reality. The drug will be available to patients.
As it relates to the broader clinical program, and I think that is the essence of your question, by the end of next year, we would have completed the remaining cardiovascular studies for obicetrapib, and these include the RUBENS trial, which is a study specifically in patients with type 2 diabetes as well as those with metabolic syndrome, but no semblance of ASCVD. This is a population of interest because there are 20, 30 million individuals that fit that risk in terms of have elevated LDL, have not had a previous event, but would benefit from a therapy like ours. The other trial is obviously PREVAIL. We remain on schedule to trigger the interim analysis by the end of this year, and we expect to hear back from the DSMB at some point in the first quarter of next year. Really, it has been a long trial.
It's a trial that we're very excited about in terms of the execution of the study and the design elements, which we think will support a positive outcome. I know the investor community is very keen to see the results. You can imagine that we are even more. That would be the next trial to read out for us. Then after that is REMBRANDT, and REMBRANDT is an outcome study for the fixed-dose combination. It's an imaging trial, and there's really nothing more powerful than an image, an image of seeing your plaque stabilize or potentially seeing plaques clear. It's akin to a cancer patient being able to visualize in an MRI, a PET scan, that their tumors have shrunk.
That's a trial that's been conducted by others in this space that resonate with clinicians, that resonate with patients, and it's a trial that we think will have important read-through and carry over to the commercial setting once that data becomes available, and that would be likely towards the end of next year.
Mm-hmm. Before we get more into PREVAIL, which is obviously top of everyone's mind, you already touched on RUBENS, and that one's perhaps maybe flown under the radar a little bit comparatively.
Yeah. But maybe just touch a little bit more on the commercial importance of that, especially as it sort of relates to the differentiation versus statins.
and the kind of diabetes impact that those drugs have.
Yes, it is an important reminder that our drug does more than simply reduce LDL. One of the benefits that we have seen of the class has been, and this is of the CETP class, a reduction in the rate of new-onset diabetes. We saw that with the programs that were evaluated by major pharma companies in the past. We clearly saw that in our one-year BROADWAY study, where we showed roughly a 15% reduction in the rate of new-onset diabetes. I cannot emphasize this enough. There is a population at risk that has diabetes, that has elevated LDL, and if those patients were put on high-intensity doses of statins, their risk of converting from pre-diabetes to diabetes increases upwards of 36%.
When you look at our BROADWAY study data, where majority of the patients were on high-intensity statin, for us to be able to offset that risk and reduce the rate of new-onset diabetes, it is a benefit and an aspect of our profile that we think will resonate with patients and clinicians, and provides an important point of differentiation versus the established class. That is the statins, the ezetimibe, as we look at the PCSK9s, where the benefit is really limited to just LDL.
Makes sense. Now moving on to PREVAIL, and perhaps very topically, we just had AHA this weekend.
Yeah. One of the key readouts there was the HORIZON study, which overall was neutral.
But if you actually dig into the supplements of the New England Journal of Medicine paper, one of the subgroups that are shown is in the patients with more than 100 milligrams per deciliter of LDL-C at baseline, which is perhaps the population that is most similar to PREVAIL. Those patients actually did see a hazard ratio of 0.83, although with error bars that did overlap one.
Sure. Still, there appears to be some trend perhaps.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
